Compare
Mitesco, Inc. vs Bioregenx, Inc. vs Blend Labs, Inc. vs Cardlytics, Inc.
| Latest fiscal year | Mitesco, Inc. MITIRevenue covers only part of its income (partial revenue) | Bioregenx, Inc. BRGX | Blend Labs, Inc. BLND | Cardlytics, Inc. CDLX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $1.85M | $123.58M | $233.27M |
| Revenue growth (YoY) | n/a | -20.8% | +6.8% | -16.2% |
| Gross margin | n/a | 81.1% | 73.8% | n/a |
| Operating margin | n/a | -67.1% | -17.6% | -43.6% |
| Net margin | n/a | -83.2% | -5.5% | -44.4% |
| Net income | $498.7K | -$1.54M | -$6.80M | -$103.49M |
| EPS (Diluted) | -$0.14 | $0.00 | -$0.10 | -$1.95 |
| Operating cash flow | -$701.6K | $39.0K | $11.51M | $9.29M |
| Free cash flow | n/a | $29.9K | -$81.0K | $8.81M |
| Cash & equivalents | $100.9K | n/a | $43.58M | $48.72M |
| Total assets | $132.1K | $411.0K | $170.04M | $285.64M |
| Total liabilities | $23.60M | $4.95M | $41.02M | $292.15M |
| Shareholders' equity | -$23.47M | -$4.54M | -$30.47M | -$6.51M |
| Return on year-end equity | n/a | n/a | n/a | n/a |
| Shares outstanding | 15.09M | 969.02M | 256.04M | 54.51M |
Revenue, most recent five fiscal years
| Fiscal year | Mitesco, Inc. | Bioregenx, Inc. | Blend Labs, Inc. | Cardlytics, Inc. |
|---|---|---|---|---|
| Latest | n/a | $1.85M Ended 2025-12-31 | $123.58M Ended 2025-12-31 | $233.27M Ended 2025-12-31 |
| 1 year earlier | n/a | $2.34M Ended 2024-12-31 | $115.76M Ended 2024-12-31 | $278.30M Ended 2024-12-31 |
| 2 years earlier | n/a | $3.41M Ended 2023-12-31 | $109.55M Ended 2023-12-31 | $309.20M Ended 2023-12-31 |
| 3 years earlier | n/a | $42.2K Ended 2022-12-31 | $235.20M Ended 2022-12-31 | $298.54M Ended 2022-12-31 |
| 4 years earlier | n/a | $198.6K Ended 2021-12-31 | $234.50M Ended 2021-12-31 | $267.12M Ended 2021-12-31 |